SCHOTT Pharma reported strong results in the third quarter of the fiscal year 2024 with revenues up 21 percent to EUR 268 million at constant currencies (Q3 2023: EUR 221 million). EBITDA at constant currencies increased even stronger by 37 percent year-on-year to EUR 76 million, despite start-up costs for the expansion projects in Hungary and Serbia.
This led to an improvement in the EBITDA margin of more than three percentage points to 28.2 percent at constant currencies (Q3 2023: 25.1 percent). As a result, SCHOTT Pharma increases its full-year 2024 revenue guidance.
“Our very strong performance in the third quarter emphasizes that market dynamics are intact and that our strategy ideally positions us to take advantage of them. The result is a consequence of our excellent strategy execution based on major pharma trends. Once again, we were able to demonstrate the value of our trusted and long-standing partnerships with our customers, which enable us to understand and address current market needs,” said Andreas Reisse, CEO of SCHOTT Pharma.
“We achieved strong results in the third quarter, in both of our segments leading to our highest ever quarterly revenues and EBITDA. Based on the first nine months results, we have increased our revenue guidance for the fiscal year 2024. Despite the challenging market environment, which we are all facing, we now expect revenue growth of 11 to 13 percent,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.
The full report is available here.